The Health Resources and Services Administration today proposed delaying until July 1, 2018 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers. The final rule has been subject to multiple delays since January, and most recently was scheduled to take effect Oct. 1, 2017. The “additional time is needed to more fully consider previous objections regarding the timing of the effective date and challenges associated with complying with the rule, as well as other objections to the rule,” the notice states. Ashley Thompson, AHA senior vice president for public policy analysis and development, said, “Given the skyrocketing prescription drug price increases that have presented hospitals and their patients with remarkable challenges, the 340B program is as critical as it has ever been in helping eligible hospitals obtain a reduced price for outpatient drugs, allowing them to stretch scarce federal resources to expand and improve access to comprehensive health care services for our nation’s most vulnerable patients. This is why we are once again disappointed in the continued delay of the 340B ceiling price and civil monetary penalties rule. HRSA’s rulemaking on these issues began seven years ago, and these multiple delays are unjustified given the exhaustive rule development process that has already occurred. We urge the agency to implement this final rule without any further delay.” Comments on the rule are due 30 days after it is published in the Federal Register.

Headline
The American Medical Association Nov. 17 released its latest annual report on health insurance competition, which found that 95% of commercial markets were…
Headline
The Medicare Part A deductible for inpatient hospital services will increase by $40 in calendar year 2026 to $1,776, the Centers for Medicare & Medicaid…
Headline
The Centers for Medicare & Medicaid Services Nov. 16 issued a proposed rule on program integrity oversight in Medicare, Medicaid, the Children’s Health…
Headline
The AHA and its co-plaintiffs Nov. 16 filed a reply brief urging a federal court to block implementation of the Health Resources and Services Administration’s…
Headline
The Centers for Medicare & Medicaid Services Nov. 5 published a final rule to codify the Medicare Drug Price Negotiation Program beginning in 2029. The…
Headline
The estimated average monthly premium for Medicare Part D stand-alone prescription drug plans is $51 for 2027, a 50% increase from $34 in 2026, for enrollees…